|
|
||||||||
Ann Thorac Surg 1995;60:599-602
© 1995 The Society of Thoracic Surgeons
Division of Cardiothoracic Surgery, University of Miami/Jackson Memorial Medical Center, and the Veterans Administration Medical Center, Miami, Florida
| Abstract |
|---|
|
|
|---|
Methods. The histories, records, operative reports, and pathology reports of the 4 patients were reviewed.
Results. The 4 surgically treated patients had stage I T1 N0 M0 lung cancer. Three patients had T4 cell counts of less than 200/µL and were managed by lobectomy. These patients died 5, 3
, and 5 months postoperatively. More recently, a fourth patient had a T4 cell count of 963/µL and was treated with wedge resection. He is currently alive 12 months postoperatively.
Conclusions. It is concluded that surgically treated patients with lung cancer, human immunodeficiency virus infection, and T4 cell counts lower than 200/µL have high mortality and morbidity. Although it may be best to base surgical intervention on the stage of the patient's human immunodeficiency virus infection, further analysis is essential to determine which subgroup of human immunodeficiency viruspositive patients, if any, would benefit from surgical treatment of lung cancer.
| Introduction |
|---|
|
|
|---|
Of all malignancies, bronchogenic carcinoma represents the most frequent cause of death in both men and women [13]. Some studies [9, 10, 12] have suggested an increased incidence of bronchogenic carcinoma in young patients with HIV; others [11] have questioned this relationship.
Since January 1986, more than 20 patients have been seen at the University of Miami/Jackson Memorial Medical Center and the Miami Veterans Administration Medical Center with concurrent HIV infection and bronchogenic carcinoma. Four of these patients were treated surgically with curative intent. We report the outcome in this group of patients and speculate on the conclusions to be drawn.
| Material and Methods |
|---|
|
|
|---|
| Results |
|---|
|
|
|---|
On March 13, 1986, he underwent right upper lobectomy for a 2 x 1 x 1-cm adenocarcinoma arising in a scar (Fig 1
). All nodes were negative, making this tumor a T1 N0 M0 stage I adenocarcinoma of the lung. A soft nodular lesion in the superior segment of the right lower lobe was excised as well and interpreted on frozen section as ``pneumonitis.'' Subsequent study revealed this lesion to be focal Pneumocystis carinii infection (Fig 2
).
|
|
The patient returned to the hospital on August 6, 1986, with small-bowel obstruction requiring exploratory laparotomy and lysis of adhesions. This procedure was complicated by sepsis and respiratory failure, and the patient died on August 17, 1986.
Patient 2
A 40-year-old HIVpositive man with a history of Pneumocystis pneumonia was seen with a 3-cm enlarging coin lesion. The T4 cell count on December 12, 1989, was 102/µL. On December 19, 1989, he underwent a right upper lobectomy. Pathologic examination revealed right upper lobe scar adenocarcinoma, a T1 N0 M0 stage I cancer.
The postoperative course was complicated by abdominal distention and severe ileus. Sigmoidoscopy was performed on January 8, 1990. The ileus eventually resolved, and the patient was discharged on January 17, 1990, postoperative day 29. He died on March 30, 1990, of pneumonia and respiratory arrest.
Patient 3
A 45-year-old man with a history of chronic pancreatitis, peptic ulcer disease, smoking, and alcohol consumption was seen with a productive cough, and a chest roentgenogram revealed a left lower lobe nodule. On March 22, 1991, he had a forced expiratory volume in 1 second of 3.28 L, 89% of predicted. On May 31, 1991, he underwent a left lower lobectomy for a 1.5 x 1.5 x 1.5 cm well-differentiated adenocarcinoma. Lymph nodes were not involved, thus making this a T1 N0 M0 stage I lung cancer. The patient did well postoperatively and was discharged on June 5, 1991, postoperative day 5.
The patient returned to the hospital on June 25, 1991, with a temperature of 39.7°C and lymphadenopathy. On June 26, he was found to be HIV positive by enzyme-linked immunosorbent assay and Western blot. On July 1, the T4 cell count was 99/µL and on July 7, 128/µL. Results of a bone marrow biopsy on July 9 were consistent with lymphoma. On July 15, the biopsy specimen from a left inguinal lymph node revealed malignant lymphoma of the large-cell immunoblastic type. The patient was offered chemotherapy but declined and left the hospital on July 16, 1991.
He was rehospitalized twice-from August 30 to September 9 for treatment of volume depletion, severe hyponatremia, atypical mycobacterial pneumonia, and sepsis and again on October 11, with fever, active tuberculosis, liver failure, and sepsis. He was discharged to hospice on October 16, 1991, in terminal condition.
Patient 4
A 53-year-old man was admitted with alcoholic pancreatitis on November 11, 1993, and a chest roentgenogram revealed a 1.5-cm left upper lobe nodule. On December 4, 1993, he was found to be HIV positive by enzyme-linked immunosorbent assay and Western blot. On December 10, 1993, a computed tomographyguided biopsy of the left upper lobe nodule was done, and the specimen revealed cellular evidence of adenocarcinoma. On December 14, 1993, the T4 cell count was 963/µL. The patient's pancreatitis eventually resolved, and on December 28, 1993, he underwent bronchoscopy, mediastinoscopy, and left thoracotomy with a generous wedge resection of the lingular mass. Final pathologic study revealed a 1.5-cm infiltrating, poorly differentiated squamous carcinoma with negative nodes, a T1 N0 M0 stage I cancer.
Postoperatively the patient did well and was discharged on January 4, 1994, postoperative day 7. He is currently alive 12 months after resection.
| Comment |
|---|
|
|
|---|
T-helper cells are T lymphocytes that play a crucial role in cell-mediated immunity and are infected and destroyed by HIV. Also known as CD4 cells, these cells are gradually depleted during the period of chronic asymptomatic HIV infection (Fig 3
). Healthy adults average 1,000 CD4 cells/µL of blood with a normal range of 600 to 1400/µL [1719]. The acute retroviral syndrome is characterized by a temporary decline in CD4 cell count followed by a return toward normal. Then, during the latent period of chronic asymptomatic HIV infection, the CD4 cell count begins to gradually decrease over several years. Patients infected with HIV experience a decline in CD4 cell count of 30 to 80 µL/y [20]. Constitutional symptoms usually begin to develop when the CD4 cell count approaches 300/µL. The average CD4 cell count seen in patients with serious opportunistic infections is 50 to 100/µL [15]. The Centers for Disease Control now stages HIV infection according to CD4 cell count: stage I is greater than or equal to 500/µL; stage II, 200 to 499/µL; and stage III, less than 200/µL [21]. As of 1992, a CD4 cell count of less than 200/µL defines AIDS whether or not opportunistic infections or malignancies are present [21].
|
Several studies [9, 10, 12] have recently reported an association between HIV infection and bronchogenic carcinoma. These studies suggest that lung cancer in HIV patients presents at a younger age and is associated with a more fulminant course with shortened survival. Adenocarcinoma is reported as the preponderant cell type.
We [25] recently reported our experience with a total of 23 patients with HIV infection and lung cancer seen between January 1986 and July 1991. These patients were noted to be younger than other patients with lung cancer, had adenocarcinoma as a preponderant histologic type, and had a median survival of only 3 months with a range of 1 month to 10 months. Here we report the results of surgical treatment with curative intent of 4 HIVinfected patients with T1 N0 M0 stage I lung cancer. Three patients had T4 cell counts lower than 200/µL and were managed by lobectomy. These patients had complicated postoperative courses and died 5, 3
, and 5 months postoperatively. More recently, a fourth patient with a T4 cell count of 963/µL was treated with wedge resection. He is currently alive 12 months postoperatively. Coincidentally, the patient with the longest survival in our larger previous series of 23 patients also had the highest CD4 cell count (968/µL).
Patients with stage I lung cancer have an overall 5-year survival rate of 60% to 70%, and those with T1 N0 M0 lesions have an overall 5-year survival rate of 68.5% to 83% [26]. In this series, the overall 1-year survival rate for HIVinfected patients with stage I T1 N0 M0 lung cancer is only 25%, and the 1-year survival rate is 0% for those with CD4 cell counts of less than 200/mm3.
Although experience with the surgical management of HIVinfected patients with lung cancer is limited, certain conclusions can be drawn. Surgical management of patients with lung cancer, HIV infection, and T4 cell counts of less than 200/µL can have high mortality and morbidity. Further analysis is essential to determine which subgroup of HIVpositive patients, if any, would benefit from standard surgical treatment of lung cancer.
One possible approach would be to base the recommendation for surgical treatment on the stage of the patient's HIV infection. Using this approach, patients with CD4 counts of greater than 500/µL would be considered appropriate candidates for resection with curative intent by the same criteria as patients without HIV infection. Patients with CD4 cell counts between 200/µL and 500/µL might be considered for limited resection. Finally, those with CD4 cell counts of less than 200/µL could be considered for palliative nonoperative management. Whether this approach proves to be reasonable in the management of HIVinfected patients with bronchogenic carcinoma awaits further experience and analysis.
It is unlikely that a single institution will have a large enough experience to develop specific treatment recommendations. Consequently, a survey of experience in the surgical treatment of lung cancer in HIVinfected patients is being undertaken. It is requested that information concerning surgical treatment of these patients be shared by completing and forwarding the survey (Appendix 1).
| Appendix 1. Survey: Surgical Treatment of Lung Cancer in Patients With Human Immunodeficiency Virus |
|---|
|
|
|---|
Surgeon's Name: ____________________
Phone Number: ______________________
Institution: ________________________
Total Number of HIVInfected Patients Undergoing Operation for Lung Cancer: _________________
Number of This Patient: __________________
PATIENT INFORMATION:
Date of Birth: _________________________
Preoperative CD4 (T4) Counts: ___ ___ ___ ___
Preoperative CD8 (T8) Counts: ___ ___ ___ ___
Date Measured: ____ ____ ____ ____
Date of Operation:____________________
Surgical Procedure:_____________________
Tissue Diagnosis (Cell Type):________________
Tumor Size:_______cm Diameter Circle One: T1 T2 T3 T4
Node Status: N0 N1 N2 N3
Metastatic Disease: M0 M1
Tumor Stage:________________________
Postoperative CD4 (T4) Counts: ___ ___ ___ ___
Postoperative CD8 (T8) Counts: ___ ___ ___ ___
Date Measured: ____ ____ ____ ____
OUTCOME:
Intraoperative Death: ______ Yes ______ No
30-Day Mortality: ________ Yes ______ No
Currently Alive: ________ Yes ______ No
Date of Last Follow-up_________________
Date of Death:_____________________
Cause of Death:______________________
Please describe perioperative and postoperative compli cations.
| Footnotes |
|---|
|
|
|---|
Address reprint requests to Dr Thurer, Division of Cardiothoracic Surgery (R-114), University of Miami School of Medicine, PO Box 016960, Miami, FL 33101.
| References |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
J Cadranel, D Garfield, A Lavole, M Wislez, B Milleron, and C Mayaud Lung cancer in HIV infected patients: facts, questions and challenges. Thorax, November 1, 2006; 61(11): 1000 - 1008. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ANN THORAC SURG | ASIAN CARDIOVASC THORAC ANN | EUR J CARDIOTHORAC SURG |
| J THORAC CARDIOVASC SURG | ICVTS | ALL CTSNet JOURNALS |